Navigation Links
ValueOptions(R) Supports New Hospital-Based Performance Measures to Help Patients Get the Best Treatment for Inpatient and Outpatient Services
Date:5/8/2009

NORFOLK, Va., May 8 /PRNewswire/ -- ValueOptions(R), Inc., the nation's largest independent behavioral health and wellness company, announces its support for the use of The Joint Commission's Hospital-Based Inpatient Psychiatric Services (HBIPS) performance measures. The basis for the recently completed pilot program was to establish a set of core performance measures to help patients receive the most appropriate and medically necessary treatment for psychiatric inpatient services and for services upon discharge. Following The Joint Commission's successful pilot testing, these performance measures are now available for widespread use in hospitals.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090106/PH55551LOGO )

There are seven HBIPS performance measures in place for hospitals which are accredited by The Joint Commission:

  • Admission screening for violence risk, substance use, psychological trauma history and patient strengths
  • Hours of physical restraint use
  • Hours of seclusion use
  • Patients discharged on multiple antipsychotic medications
  • Patients discharged on multiple antipsychotic medications with appropriate justification
  • Post discharge continuing care plan created
  • Post discharge continuing care plan transmitted to next level of care provider upon discharge

"Coordination between Inpatient and Outpatient providers in these areas will help to ensure positive outcomes for members and their families," said Renee Abdou-Malta, vice president of National Network Services for ValueOptions(R). "We very much encourage our Joint Commission-accredited providers to work together in this manner."

"Thorough assessments which lead to individualized treatment plans as well as discharge coordination are areas that ValueOptions(R) advocates," said Hal Levine, D.O., chief medical officer for ValueOptions(R). "We routinely encourage hospitals to minimize their use of seclusion, restraint and polypharmacy. The Joint Commission's measures will help all parties involved to provide optimal services when treating members."

More information regarding The Joint Commission's HBIPS performance measures can be found on The Joint Commission's Web site.

About ValueOptions(R), Inc.

ValueOptions(R), Inc., the nation's largest independent behavioral health and wellness company, provides services to more than 23 million individuals through a variety of contracts with state and county agencies and, additionally, with health plans and employers. ValueOptions(R) is a national behavioral health and wellness company that specializes in management for all behavioral health issues and promotes health and wellness through innovative programs. ValueOptions(R) mission is to improve the health and wellness for the people it serves.

www.ValueOptions.com


'/>"/>
SOURCE ValueOptions, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. First Human Study to Show Sun Chlorella A Supports Heart Health
2. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
3. New Study Confirms That the Supports Intensity Scale Assessment is Effective in Measuring the Support Needs of People With Intellectual Disability and Making Funding Decisions
4. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
5. APTA Supports Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
6. Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials
7. DSMB Again Supports Continuation of Alimera Sciences Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
8. New Data Presented at WCTRIMS* Supports the Importance of Early and Sustained Treatment with Betaseron(R)
9. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
10. Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
11. Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
(Date:6/23/2016)... -- , , , WHEN: , ... , , , LOCATION: , , , Online, with free ... EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice President ... Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... is witnessing an exceptional era. Several new demand spaces, such as ...
Breaking Medicine Technology:
(Date:6/27/2016)... KS (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com ... retailers of Eyeglasses . , Millions of individuals in the United States and ... have become a way to both correct vision and make a fashion statement. Even ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
Breaking Medicine News(10 mins):